首页 > 最新文献

Case Reports in Hematology最新文献

英文 中文
"A Dangerous Black Box:" Idiopathic Hemophagocytic Lymphohistiocytosis in Adult Patients-A Case Report and Review of the Literature. “一个危险的黑盒子:”成人患者的特发性噬血细胞淋巴组织细胞病-一例报告和文献综述。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2022-01-01 DOI: 10.1155/2022/5867129
Nada Agbariah, Javier Sanz, Alicia Rovó

Hemophagocytic lymphohistiocytosis (HLH) is a rare potentially life-threatening condition characterized by aberrant inflammation that can be related to genetic or sporadic forms. In both forms, triggering factors may be involved. Early detection of the underlying cause is crucial for therapeutic decision, while early intervention might be associated with better outcomes. The largest descriptions in the literature on HLH refer to pediatric cases. Adolescents and adults may also be affected, but there is scarce evidence regarding their diagnosis and management. We describe here the case of a 68-year-old Swiss woman with HLH, in whom an extensive search for underlying causes was performed, but neither trigger nor pathogenic variant was found. An early intervention first with dexamethasone and later with cyclosporine was performed. The patient showed a favorable response and did not require further hospitalization; however, one year after diagnosis, it was not possible to suspend cyclosporine due to recurrence of laboratory inflammation signs by drug tapering. The occurrence of HLH idiopathic forms represents a challenge; failure to identify the underlying triggering cause generates uncertainty, endless diagnostic investigations, and consequently additional delays in the treatment. This manuscript addresses the difficulties on this issue.

噬血细胞性淋巴组织细胞增多症(HLH)是一种罕见的潜在威胁生命的疾病,其特征是异常炎症,可能与遗传或散发形式有关。在这两种形式中,都可能涉及触发因素。早期发现潜在原因对于治疗决策至关重要,而早期干预可能与更好的结果相关。文献中对HLH的最大描述是儿科病例。青少年和成人也可能受到影响,但关于其诊断和管理的证据很少。我们在这里描述一个68岁的瑞士妇女HLH的情况下,其中进行了广泛的搜索潜在的原因,但既没有触发也没有致病变异被发现。早期干预首先使用地塞米松,后来使用环孢素。患者表现出良好的反应,不需要进一步住院;然而,在诊断一年后,由于实验室炎症症状复发,无法通过药物减量停用环孢素。HLH特发性形式的出现是一个挑战;未能确定潜在的触发原因会产生不确定性,无休止的诊断调查,从而导致治疗的进一步延误。这份手稿阐述了这个问题上的难点。
{"title":"\"A Dangerous Black Box:\" Idiopathic Hemophagocytic Lymphohistiocytosis in Adult Patients-A Case Report and Review of the Literature.","authors":"Nada Agbariah,&nbsp;Javier Sanz,&nbsp;Alicia Rovó","doi":"10.1155/2022/5867129","DOIUrl":"https://doi.org/10.1155/2022/5867129","url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH) is a rare potentially life-threatening condition characterized by aberrant inflammation that can be related to genetic or sporadic forms. In both forms, triggering factors may be involved. Early detection of the underlying cause is crucial for therapeutic decision, while early intervention might be associated with better outcomes. The largest descriptions in the literature on HLH refer to pediatric cases. Adolescents and adults may also be affected, but there is scarce evidence regarding their diagnosis and management. We describe here the case of a 68-year-old Swiss woman with HLH, in whom an extensive search for underlying causes was performed, but neither trigger nor pathogenic variant was found. An early intervention first with dexamethasone and later with cyclosporine was performed. The patient showed a favorable response and did not require further hospitalization; however, one year after diagnosis, it was not possible to suspend cyclosporine due to recurrence of laboratory inflammation signs by drug tapering. The occurrence of HLH idiopathic forms represents a challenge; failure to identify the underlying triggering cause generates uncertainty, endless diagnostic investigations, and consequently additional delays in the treatment. This manuscript addresses the difficulties on this issue.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2022 ","pages":"5867129"},"PeriodicalIF":0.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10704928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Chronic Eosinophilic Leukemia Presenting as Cardiac Failure. 慢性嗜酸性粒细胞白血病表现为心力衰竭。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2022-01-01 DOI: 10.1155/2022/7841310
Nii Boi-Doku Pepra-Ameyaw, William Kwasi Ghunney, Eugene Baafi Ampofo, Edeghonghon Olayemi

Chronic eosinophilic leukemia (CEL) is a rare chronic myeloproliferative disorder characterized by sustained eosinophilia. Although the incidence of CEL is uncertain, it can be clinically devastating as it has a propensity to affect several important organ systems. This is of particular significance in Sub-Saharan Africa where helminthic infections are a more prevalent cause of eosinophilia. To the best of our knowledge, we present the first reported case of CEL complicated by cardiac disease in a Ghanaian. He presented with a history of orthopnoea and dyspnoea on exertion, and examination revealed a pansystolic murmur over the mitral region and moderate splenomegaly. Good symptomatic control was achieved using hydroxyurea after which haematologic and cytogenetic remission was achieved after 12 weeks on a tyrosine kinase inhibitor. Physicians working in low resource environments should exclude clonality in patients presenting with eosinophilia and end-organ damage.

慢性嗜酸性粒细胞白血病(CEL)是一种罕见的慢性骨髓增生性疾病,以持续嗜酸性粒细胞增多为特征。虽然CEL的发病率尚不确定,但它可能是临床上毁灭性的,因为它有影响几个重要器官系统的倾向。这在撒哈拉以南非洲尤其重要,因为蠕虫感染是嗜酸性粒细胞增多症更普遍的原因。据我们所知,我们提出了第一例报告的CEL合并心脏病在加纳人。他有直立呼吸和用力时呼吸困难的病史,检查发现二尖瓣区有全收缩期杂音和中度脾肿大。使用羟基脲获得了良好的症状控制,在使用酪氨酸激酶抑制剂12周后,血液学和细胞遗传学得到缓解。在低资源环境中工作的医生应排除出现嗜酸性粒细胞增多和终末器官损伤的患者的克隆性。
{"title":"Chronic Eosinophilic Leukemia Presenting as Cardiac Failure.","authors":"Nii Boi-Doku Pepra-Ameyaw,&nbsp;William Kwasi Ghunney,&nbsp;Eugene Baafi Ampofo,&nbsp;Edeghonghon Olayemi","doi":"10.1155/2022/7841310","DOIUrl":"https://doi.org/10.1155/2022/7841310","url":null,"abstract":"<p><p>Chronic eosinophilic leukemia (CEL) is a rare chronic myeloproliferative disorder characterized by sustained eosinophilia. Although the incidence of CEL is uncertain, it can be clinically devastating as it has a propensity to affect several important organ systems. This is of particular significance in Sub-Saharan Africa where helminthic infections are a more prevalent cause of eosinophilia. To the best of our knowledge, we present the first reported case of CEL complicated by cardiac disease in a Ghanaian. He presented with a history of orthopnoea and dyspnoea on exertion, and examination revealed a pansystolic murmur over the mitral region and moderate splenomegaly. Good symptomatic control was achieved using hydroxyurea after which haematologic and cytogenetic remission was achieved after 12 weeks on a tyrosine kinase inhibitor. Physicians working in low resource environments should exclude clonality in patients presenting with eosinophilia and end-organ damage.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2022 ","pages":"7841310"},"PeriodicalIF":0.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10495586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Treatment of Concomitant Pleural Mucosa-Associated Lymphoid Tissue Lymphoma and Monoclonal Gammopathy of Undetermined Significance with Lenalidomide, Rituximab, and Dexamethasone. 来那度胺、利妥昔单抗和地塞米松成功治疗伴发性胸膜黏膜相关淋巴组织淋巴瘤和意义不明的单克隆伽玛病。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2022-01-01 DOI: 10.1155/2022/2027027
Yoshiki Uemura, Risa Maeda, Hiroyoshi Saegusa

Concomitant plasma cell and B cell neoplasms in a single patient have been infrequently reported. It is known that the prognosis of these patients is worse than that of patients with single-disease onset. Generally, the chemotherapy specific for each disease is provided sequentially. It has been suggested that the specific chemotherapy for lymphoma could lead to the occurrence of refractory multiple myeloma (MM). We present a case with the concomitant occurrence of mucosa-associated lymphoid tissue (MALT) lymphoma and monoclonal gammopathy of undetermined significance (MGUS). MGUS does not usually require aggressive treatment. However, the potential adverse effects of MGUS on the treatment course of the B cell lymphoma were concerning. Therefore, we explored a new therapeutic approach that is simultaneously effective against both diseases. Combination therapy of lenalidomide (LEN) and rituximab (RIT) gained indication for follicular lymphoma and MALT lymphoma recently. LEN is also a key drug in MM treatment. Both diseases in our patient were effectively treated with the combination of LEN, RIT, and dexamethasone. With this combination therapy, we expect a prognostic improvement in concomitant MM and B cell lymphoma cases.

在单个患者中合并浆细胞和B细胞肿瘤的报道并不多见。据了解,这些患者的预后比单一发病的患者差。一般来说,针对每种疾病的特异性化疗是按顺序提供的。有研究表明,针对淋巴瘤的特异性化疗可导致难治性多发性骨髓瘤(MM)的发生。我们报告一例伴随发生粘膜相关淋巴组织(MALT)淋巴瘤和意义不明的单克隆伽玛病(MGUS)。MGUS通常不需要积极治疗。然而,MGUS对B细胞淋巴瘤治疗过程的潜在不良影响令人担忧。因此,我们探索了一种同时有效对抗这两种疾病的新治疗方法。来那度胺(LEN)联合利妥昔单抗(rituximab)治疗滤泡性淋巴瘤和MALT淋巴瘤最近获得了适应症。LEN也是MM治疗的关键药物。本例患者两种疾病均经LEN、RIT和地塞米松联合有效治疗。通过这种联合治疗,我们期望合并MM和B细胞淋巴瘤病例的预后得到改善。
{"title":"Successful Treatment of Concomitant Pleural Mucosa-Associated Lymphoid Tissue Lymphoma and Monoclonal Gammopathy of Undetermined Significance with Lenalidomide, Rituximab, and Dexamethasone.","authors":"Yoshiki Uemura,&nbsp;Risa Maeda,&nbsp;Hiroyoshi Saegusa","doi":"10.1155/2022/2027027","DOIUrl":"https://doi.org/10.1155/2022/2027027","url":null,"abstract":"<p><p>Concomitant plasma cell and B cell neoplasms in a single patient have been infrequently reported. It is known that the prognosis of these patients is worse than that of patients with single-disease onset. Generally, the chemotherapy specific for each disease is provided sequentially. It has been suggested that the specific chemotherapy for lymphoma could lead to the occurrence of refractory multiple myeloma (MM). We present a case with the concomitant occurrence of mucosa-associated lymphoid tissue (MALT) lymphoma and monoclonal gammopathy of undetermined significance (MGUS). MGUS does not usually require aggressive treatment. However, the potential adverse effects of MGUS on the treatment course of the B cell lymphoma were concerning. Therefore, we explored a new therapeutic approach that is simultaneously effective against both diseases. Combination therapy of lenalidomide (LEN) and rituximab (RIT) gained indication for follicular lymphoma and MALT lymphoma recently. LEN is also a key drug in MM treatment. Both diseases in our patient were effectively treated with the combination of LEN, RIT, and dexamethasone. With this combination therapy, we expect a prognostic improvement in concomitant MM and B cell lymphoma cases.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2022 ","pages":"2027027"},"PeriodicalIF":0.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10620256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Diagnosis Is in the Smear: A Case and Review of Spur Cell Anemia in Cirrhosis. 在涂片中诊断:肝硬化骨刺细胞贫血1例回顾。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2021-01-01 DOI: 10.1155/2021/8883335
Gabriella A Raffa, Diana M Byrnes, John J Byrnes

The etiology of anemia in liver cirrhosis is multifactorial; one less recognized cause is hemolytic anemia due to spur cells, known as spur cell anemia. We present the case of a 57-year-old woman with alcoholic cirrhosis who presented with symptomatic macrocytic anemia with a hemoglobin level of 7.4 g/dL and signs of decompensated liver disease. Notably, she had no signs of overt bleeding. Further workup was consistent with hemolysis, with peripheral smear demonstrating spur cells. The patient was treated with both steroids and IVIG, although she eventually expired. The characteristic morphology of spur cells is due to alteration of the lipid composition of the erythrocyte membrane, changing its shape and leading to splenic sequestration and destruction. Characteristic of this disorder is an increased ratio of cholesterol to phospholipid on the membrane, as well as low levels of apolipoproteins and low- and high-density lipoproteins. The presence of spur cells is an indicator of poor prognosis and high risk of mortality. Currently, the only definitive cure is liver transplantation. There is a paucity of literature on the prevalence of this phenomenon and even less about treatment. This case highlights the importance of recognition of spur cell anemia as a cause of anemia in cirrhosis as well as the importance of the peripheral smear in the diagnostic workup. Early recognition can lead to avoidance of unnecessary procedures. Further research is needed to elucidate the true prevalence of spur cell anemia and examine further treatment options.

肝硬化贫血的病因是多因素的;一种不太为人所知的原因是由刺细胞引起的溶血性贫血,称为刺细胞贫血。我们提出的情况下,57岁的女性酒精性肝硬化谁提出了有症状的大细胞性贫血,血红蛋白水平为7.4 g/dL和代偿性肝病的迹象。值得注意的是,她没有明显出血的迹象。进一步检查与溶血一致,外周涂片显示骨刺细胞。患者接受了类固醇和IVIG的治疗,但最终还是去世了。骨刺细胞的特征形态是由于红细胞膜脂质组成的改变,改变了其形状,导致脾隔离和破坏。这种疾病的特征是膜上胆固醇与磷脂的比例增加,以及载脂蛋白和低脂蛋白和高密度脂蛋白的低水平。骨刺细胞的存在是预后不良和死亡率高的一个指标。目前,唯一确定的治疗方法是肝移植。关于这种现象的流行程度的文献很少,关于治疗的文献就更少了。本病例强调了认识到刺细胞贫血是肝硬化贫血的原因的重要性,以及外周血涂片在诊断检查中的重要性。早期识别可以避免不必要的程序。需要进一步的研究来阐明刺细胞贫血的真实患病率,并研究进一步的治疗方案。
{"title":"The Diagnosis Is in the Smear: A Case and Review of Spur Cell Anemia in Cirrhosis.","authors":"Gabriella A Raffa,&nbsp;Diana M Byrnes,&nbsp;John J Byrnes","doi":"10.1155/2021/8883335","DOIUrl":"https://doi.org/10.1155/2021/8883335","url":null,"abstract":"<p><p>The etiology of anemia in liver cirrhosis is multifactorial; one less recognized cause is hemolytic anemia due to spur cells, known as spur cell anemia. We present the case of a 57-year-old woman with alcoholic cirrhosis who presented with symptomatic macrocytic anemia with a hemoglobin level of 7.4 g/dL and signs of decompensated liver disease. Notably, she had no signs of overt bleeding. Further workup was consistent with hemolysis, with peripheral smear demonstrating spur cells. The patient was treated with both steroids and IVIG, although she eventually expired. The characteristic morphology of spur cells is due to alteration of the lipid composition of the erythrocyte membrane, changing its shape and leading to splenic sequestration and destruction. Characteristic of this disorder is an increased ratio of cholesterol to phospholipid on the membrane, as well as low levels of apolipoproteins and low- and high-density lipoproteins. The presence of spur cells is an indicator of poor prognosis and high risk of mortality. Currently, the only definitive cure is liver transplantation. There is a paucity of literature on the prevalence of this phenomenon and even less about treatment. This case highlights the importance of recognition of spur cell anemia as a cause of anemia in cirrhosis as well as the importance of the peripheral smear in the diagnostic workup. Early recognition can lead to avoidance of unnecessary procedures. Further research is needed to elucidate the true prevalence of spur cell anemia and examine further treatment options.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2021 ","pages":"8883335"},"PeriodicalIF":0.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10346158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia. 慢性髓性白血病患者主动停用酪氨酸激酶抑制剂。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2020-01-01 DOI: 10.1155/2020/9571691
Stephen E Langabeer, Rehman Faryal, Michael O'Dwyer, Sorcha Ní Loingsigh

The introduction of tyrosine kinase inhibitors (TKI) has revolutionised the management of patients with chronic myeloid leukemia (CML) over the last twenty years, but despite significant improvements in survival, patients exhibit long-term side effects that impact on quality of life. A major advance in CML management has been the ability to discontinue TKI therapy achieving a treatment-free remission (TFR), yet this option is only available to eligible patients who present with low-risk disease and who subsequently attain deep and sustained molecular responses. A case is described of a patient with CML who self-initiated stopping of TKI therapy when in a less than optimal molecular remission. Despite this action, the patient continues to experience a TFR with prospective close molecular monitoring performed. It is emphasized that this approach may lead to ineffective treatment discontinuation, molecular relapse, and increased patient anxiety. As TFR for patients with CML moves from clinical trials into routine clinical practice, emphasis is placed on adherence to (evolving) guidelines critical to ensure optimal counselling, selection, monitoring, and continued management of patients whether TFR is successful or not.

在过去的二十年里,酪氨酸激酶抑制剂(TKI)的引入彻底改变了慢性髓性白血病(CML)患者的治疗,但尽管生存率有显著提高,但患者表现出影响生活质量的长期副作用。CML管理的一个主要进展是能够停止TKI治疗以实现无治疗缓解(TFR),但这种选择仅适用于低风险疾病且随后获得深度和持续分子反应的符合条件的患者。一个病例描述了CML患者谁主动停止TKI治疗时,在一个不理想的分子缓解。尽管采取了这一措施,患者仍继续经历TFR,并进行了前瞻性的密切分子监测。强调这种方法可能导致无效的治疗中断,分子复发,并增加患者的焦虑。随着慢性粒细胞白血病患者的TFR从临床试验进入常规临床实践,重点放在遵守(不断发展的)指南上,这些指南对于确保最佳的咨询、选择、监测和患者的持续管理至关重要,无论TFR是否成功。
{"title":"Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia.","authors":"Stephen E Langabeer,&nbsp;Rehman Faryal,&nbsp;Michael O'Dwyer,&nbsp;Sorcha Ní Loingsigh","doi":"10.1155/2020/9571691","DOIUrl":"https://doi.org/10.1155/2020/9571691","url":null,"abstract":"<p><p>The introduction of tyrosine kinase inhibitors (TKI) has revolutionised the management of patients with chronic myeloid leukemia (CML) over the last twenty years, but despite significant improvements in survival, patients exhibit long-term side effects that impact on quality of life. A major advance in CML management has been the ability to discontinue TKI therapy achieving a treatment-free remission (TFR), yet this option is only available to eligible patients who present with low-risk disease and who subsequently attain deep and sustained molecular responses. A case is described of a patient with CML who self-initiated stopping of TKI therapy when in a less than optimal molecular remission. Despite this action, the patient continues to experience a TFR with prospective close molecular monitoring performed. It is emphasized that this approach may lead to ineffective treatment discontinuation, molecular relapse, and increased patient anxiety. As TFR for patients with CML moves from clinical trials into routine clinical practice, emphasis is placed on adherence to (evolving) guidelines critical to ensure optimal counselling, selection, monitoring, and continued management of patients whether TFR is successful or not.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2020 ","pages":"9571691"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9571691","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10482689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
An Unusual Initial Presentation of Diffuse Large B-Cell Lymphoma as Recurrent Syncope. 弥漫性大b细胞淋巴瘤复发性晕厥的不寻常首发表现。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2019-12-26 eCollection Date: 2019-01-01 DOI: 10.1155/2019/1082543
Kunhwa Kim, Harpreet Kaur, Matthew Chan, Manju Balasubramanian, Sorab Gupta, Vinicius M Jorge

We describe a rare presentation of diffuse large B-cell Lymphoma (DLBCL) with recurrent episodes of syncope. During the workup for syncope, the patient was incidentally found to have an extensive mass in the left thorax, which was later diagnosed as stage 2 bulky disease DLBCL. This is the rare case of lymphoma presenting as recurrent syncope without cardiac involvement. The patient did not have any further episodes of syncope after her successful treatment of DLBCL.

我们报告一例罕见的弥漫性大b细胞淋巴瘤(DLBCL)伴复发性晕厥发作。在对晕厥的检查中,患者偶然发现左胸有一个广泛的肿块,后来被诊断为2期大体积DLBCL。这是一个罕见的淋巴瘤病例,表现为复发性晕厥而不累及心脏。患者在成功治疗DLBCL后没有再发生晕厥发作。
{"title":"An Unusual Initial Presentation of Diffuse Large B-Cell Lymphoma as Recurrent Syncope.","authors":"Kunhwa Kim,&nbsp;Harpreet Kaur,&nbsp;Matthew Chan,&nbsp;Manju Balasubramanian,&nbsp;Sorab Gupta,&nbsp;Vinicius M Jorge","doi":"10.1155/2019/1082543","DOIUrl":"https://doi.org/10.1155/2019/1082543","url":null,"abstract":"<p><p>We describe a rare presentation of diffuse large B-cell Lymphoma (DLBCL) with recurrent episodes of syncope. During the workup for syncope, the patient was incidentally found to have an extensive mass in the left thorax, which was later diagnosed as stage 2 bulky disease DLBCL. This is the rare case of lymphoma presenting as recurrent syncope without cardiac involvement. The patient did not have any further episodes of syncope after her successful treatment of DLBCL.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2019 ","pages":"1082543"},"PeriodicalIF":0.7,"publicationDate":"2019-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/1082543","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37554267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A Massive Extradural Hematoma in Sickle Cell Disease and the Importance of Rapid Neuroimaging. 镰状细胞病的大量硬膜外血肿和快速神经成像的重要性。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2019-12-18 eCollection Date: 2019-01-01 DOI: 10.1155/2019/1742472
Per Ole Iversen, Mboka Jacob, Jamila Makame, Mclean Abisay, Mbonea Yonazi, Anna Schuh, Julie Makani

Sickle cell disease (SCD) is an inherited hemoglobinopathy leading to several serious organ complications and early death. It is mostly found in equatorial countries like Tanzania. Extradural hematoma (EDH) is a rare, but serious complication to SCD and may have debilitating consequences. Hitherto, there is no report of EDH in SCD where neuroimaging has been available before, during, and after such an event. Here, we describe a young female SCD patient who developed EDH that required surgical evacuation. She had made full recovery after three months. Neuroimaging performed two years prior to this event was unremarkable except for multiple small cerebral infarcts. On admission, neuroimaging revealed a subgaleal hematoma, possibly indicating disruption of the skull cortex due to increased hematopoiesis. Three months after evacuation of the hematoma, neuroimaging showed evidence of brain atrophy and the previously reported cerebral infarcts and multifocal bone infarction, but no vasculopathy. Possibly, disruption of the skull cortex with subsequent bleeding caused the EDH. As the differential diagnoses of neurological complications in SCD are many and some complications are reversible, neuroimaging should be performed without delay.

镰状细胞病(SCD)是一种遗传性血红蛋白病,可导致几种严重的器官并发症和早期死亡。它主要分布在坦桑尼亚等赤道国家。硬膜外血肿(EDH)是一种罕见但严重的SCD并发症,并可能导致衰弱的后果。到目前为止,还没有在SCD发生之前、期间和之后进行神经影像学检查的EDH报告。在这里,我们描述了一个年轻的女性SCD患者谁发展EDH,需要手术疏散。三个月后她完全康复了。在此事件发生前两年进行的神经影像学检查除多发小脑梗死外无显著差异。入院时,神经影像学显示无骨瓣下血肿,可能表明由于造血功能增加导致颅骨皮质破裂。血肿清除3个月后,神经影像学显示脑萎缩和先前报道的脑梗死和多灶性骨梗死的证据,但没有血管病变。可能是颅骨皮质破裂和随后的出血导致了EDH。由于SCD神经系统并发症的鉴别诊断很多,而且有些并发症是可逆的,因此应及时进行神经影像学检查。
{"title":"A Massive Extradural Hematoma in Sickle Cell Disease and the Importance of Rapid Neuroimaging.","authors":"Per Ole Iversen,&nbsp;Mboka Jacob,&nbsp;Jamila Makame,&nbsp;Mclean Abisay,&nbsp;Mbonea Yonazi,&nbsp;Anna Schuh,&nbsp;Julie Makani","doi":"10.1155/2019/1742472","DOIUrl":"https://doi.org/10.1155/2019/1742472","url":null,"abstract":"<p><p>Sickle cell disease (SCD) is an inherited hemoglobinopathy leading to several serious organ complications and early death. It is mostly found in equatorial countries like Tanzania. Extradural hematoma (EDH) is a rare, but serious complication to SCD and may have debilitating consequences. Hitherto, there is no report of EDH in SCD where neuroimaging has been available before, during, and after such an event. Here, we describe a young female SCD patient who developed EDH that required surgical evacuation. She had made full recovery after three months. Neuroimaging performed two years prior to this event was unremarkable except for multiple small cerebral infarcts. On admission, neuroimaging revealed a subgaleal hematoma, possibly indicating disruption of the skull cortex due to increased hematopoiesis. Three months after evacuation of the hematoma, neuroimaging showed evidence of brain atrophy and the previously reported cerebral infarcts and multifocal bone infarction, but no vasculopathy. Possibly, disruption of the skull cortex with subsequent bleeding caused the EDH. As the differential diagnoses of neurological complications in SCD are many and some complications are reversible, neuroimaging should be performed without delay.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2019 ","pages":"1742472"},"PeriodicalIF":0.7,"publicationDate":"2019-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/1742472","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37535926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Association of Immune Thrombocytopenia and T-Lymphoblastic Lymphoma in a Pediatric Patient. 儿童患者免疫性血小板减少症与t淋巴母细胞淋巴瘤的关系。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2019-12-17 eCollection Date: 2019-01-01 DOI: 10.1155/2019/1425151
Ryan A Denu, Daniel R Matson, Matthew J Davis, Natalie J Tedford, Christine E Brichta, Carol A Diamond, Margo L Hoover-Regan

Immune thrombocytopenia (ITP) is characterized by isolated thrombocytopenia of unclear etiology. We present a unique case of an 8-year-old girl with chronic ITP who was subsequently diagnosed with T-lymphoblastic lymphoma at age 11. The clinical course was complicated by the occurrence of nonepileptiform events with bizarre behavior changes following the administration of nelarabine and intrathecal and high-dose systemic methotrexate. This case highlights an unusual co-occurrence of hematologic malignancy and chronic ITP in an otherwise healthy child. We speculate that underlying genetic or immunologic lesions may predispose a subset of pediatric ITP patients to the development of hematologic malignancies.

免疫性血小板减少症(ITP)以病因不明的孤立性血小板减少为特征。我们提出一个独特的案例,一个8岁的女孩慢性ITP谁随后被诊断为t淋巴母细胞淋巴瘤在11岁。在给予奈拉宾、鞘内注射和大剂量全身甲氨蝶呤后,临床过程因非癫痫样事件的发生和奇怪的行为改变而复杂化。本病例强调了一个不寻常的血液恶性肿瘤和慢性ITP在其他健康的儿童共同发生。我们推测,潜在的遗传或免疫病变可能使一部分儿童ITP患者易患血液系统恶性肿瘤。
{"title":"Association of Immune Thrombocytopenia and T-Lymphoblastic Lymphoma in a Pediatric Patient.","authors":"Ryan A Denu,&nbsp;Daniel R Matson,&nbsp;Matthew J Davis,&nbsp;Natalie J Tedford,&nbsp;Christine E Brichta,&nbsp;Carol A Diamond,&nbsp;Margo L Hoover-Regan","doi":"10.1155/2019/1425151","DOIUrl":"https://doi.org/10.1155/2019/1425151","url":null,"abstract":"<p><p>Immune thrombocytopenia (ITP) is characterized by isolated thrombocytopenia of unclear etiology. We present a unique case of an 8-year-old girl with chronic ITP who was subsequently diagnosed with T-lymphoblastic lymphoma at age 11. The clinical course was complicated by the occurrence of nonepileptiform events with bizarre behavior changes following the administration of nelarabine and intrathecal and high-dose systemic methotrexate. This case highlights an unusual co-occurrence of hematologic malignancy and chronic ITP in an otherwise healthy child. We speculate that underlying genetic or immunologic lesions may predispose a subset of pediatric ITP patients to the development of hematologic malignancies.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2019 ","pages":"1425151"},"PeriodicalIF":0.7,"publicationDate":"2019-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/1425151","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37535925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Central Nervous System Double Relapse of Acute Promyelocytic Leukemia and Acute Myelomonocytic Leukemia. 急性早幼粒细胞白血病和急性髓单细胞白血病的中枢神经系统双重复发。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2019-12-17 eCollection Date: 2019-01-01 DOI: 10.1155/2019/4907352
Laura M Stanko, Vishnu Reddy, Fady M Mikhail, Nikolaos Papadantonakis

Relapse of acute promyelocytic leukemia (APL) and non-M3-acute myeloid leukemia in the central nervous system (CNS) are rare events. Here, we describe a case of simultaneous relapses of APL and acute myelomonocytic leukemia on the CNS of a patient after allogeneic bone marrow transplant. This extremely unusual case highlights the difficulties that CNS leukemia relapses pose in the post-transplant setting.

急性早幼粒细胞白血病(APL)和非m3急性髓性白血病在中枢神经系统(CNS)复发是罕见的事件。在这里,我们描述了一例同时复发的APL和急性髓细胞白血病的患者在异基因骨髓移植后的中枢神经系统。这个极不寻常的病例突出了移植后中枢神经系统白血病复发的困难。
{"title":"Central Nervous System Double Relapse of Acute Promyelocytic Leukemia and Acute Myelomonocytic Leukemia.","authors":"Laura M Stanko,&nbsp;Vishnu Reddy,&nbsp;Fady M Mikhail,&nbsp;Nikolaos Papadantonakis","doi":"10.1155/2019/4907352","DOIUrl":"https://doi.org/10.1155/2019/4907352","url":null,"abstract":"<p><p>Relapse of acute promyelocytic leukemia (APL) and non-M3-acute myeloid leukemia in the central nervous system (CNS) are rare events. Here, we describe a case of simultaneous relapses of APL and acute myelomonocytic leukemia on the CNS of a patient after allogeneic bone marrow transplant. This extremely unusual case highlights the difficulties that CNS leukemia relapses pose in the post-transplant setting.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2019 ","pages":"4907352"},"PeriodicalIF":0.7,"publicationDate":"2019-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/4907352","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37535927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
An Unusual Presentation of T-Cell Lymphoblastic Lymphoma with Isolated Renal Involvement. 孤立性肾受累的t细胞淋巴母细胞淋巴瘤的罕见表现。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2019-12-10 eCollection Date: 2019-01-01 DOI: 10.1155/2019/2802141
Sultan Aydın Köker, Alper Koker, Adem Yasin Köksoy, Yasemin Kayadibi, Ülkü Gül Şiraz, Emine Tekin

The clinical presentation of Non-Hodgkin lymphoma (NHL) is frequently associated with the involvement of the abdomen and mediastinal lymphadenopathies, but rarely the kidney, ovaries, and testicles. Here, we report a rare case of T-cell lymphoblastic lymphoma (T-LBL) presenting with bilateral nephromegaly without acute renal failure (ARF) as the first manifestation. A 30-month-old boy was admitted to the department of pediatric nephrology exhibiting abdominal distension. Physical examination revealed bilateral renal palpation up to the inguinal region. Elevated lactate dehydrogenase (LDH) levels were detected in his blood. Bilateral diffuse enlarged kidneys with increased hypoechogenicity were found on abdominal ultrasonography. In the next step, contrast-enhanced computed tomography showed diffusely enlarged kidneys, which were compressing the intestinal bowels and midline structures. Renal biopsy demonstrated precursor T-LBL. We wish to report our patient with renal T-LBL presenting with diffuse renal enlargement, which has rarely been reported in the literature.

非霍奇金淋巴瘤(NHL)的临床表现通常与腹部和纵隔淋巴结病变有关,但很少累及肾脏、卵巢和睾丸。在此,我们报告一例罕见的t细胞淋巴母细胞淋巴瘤(T-LBL),以双侧肾肿大为首发表现,无急性肾功能衰竭(ARF)。一个30个月大的男孩被收住儿科肾脏病科表现腹胀。体格检查显示双侧肾触诊至腹股沟区。血液中乳酸脱氢酶(LDH)水平升高。腹部超声检查发现双侧弥漫性肾脏增大,低回声增强。下一步,增强计算机断层扫描显示弥漫性肾脏肿大,压迫肠子和中线结构。肾活检显示前驱T-LBL。我们希望报告我们的患者肾T-LBL表现为弥漫性肾脏增大,这在文献中很少报道。
{"title":"An Unusual Presentation of T-Cell Lymphoblastic Lymphoma with Isolated Renal Involvement.","authors":"Sultan Aydın Köker,&nbsp;Alper Koker,&nbsp;Adem Yasin Köksoy,&nbsp;Yasemin Kayadibi,&nbsp;Ülkü Gül Şiraz,&nbsp;Emine Tekin","doi":"10.1155/2019/2802141","DOIUrl":"https://doi.org/10.1155/2019/2802141","url":null,"abstract":"<p><p>The clinical presentation of Non-Hodgkin lymphoma (NHL) is frequently associated with the involvement of the abdomen and mediastinal lymphadenopathies, but rarely the kidney, ovaries, and testicles. Here, we report a rare case of T-cell lymphoblastic lymphoma (T-LBL) presenting with bilateral nephromegaly without acute renal failure (ARF) as the first manifestation. A 30-month-old boy was admitted to the department of pediatric nephrology exhibiting abdominal distension. Physical examination revealed bilateral renal palpation up to the inguinal region. Elevated lactate dehydrogenase (LDH) levels were detected in his blood. Bilateral diffuse enlarged kidneys with increased hypoechogenicity were found on abdominal ultrasonography. In the next step, contrast-enhanced computed tomography showed diffusely enlarged kidneys, which were compressing the intestinal bowels and midline structures. Renal biopsy demonstrated precursor T-LBL. We wish to report our patient with renal T-LBL presenting with diffuse renal enlargement, which has rarely been reported in the literature.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2019 ","pages":"2802141"},"PeriodicalIF":0.7,"publicationDate":"2019-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/2802141","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37498494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
期刊
Case Reports in Hematology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1